Myo-Inositol vs D-Chiro-Inositol: Why the 40:1 Ratio Exists

What Is the Difference Between Myo-Inositol and D-Chiro-Inositol?

Inositol has 9 possible stereoisomer forms, and myo-inositol (MI) and D-chiro-inositol (DCI) are the 2 that matter for PCOS — the same atoms arranged differently, both acting as second messengers in the insulin-signalling pathway. An insulin-dependent enzyme called an epimerase converts MI into DCI inside the body, and the two isomers do not do identical jobs once converted: MI supports glucose uptake broadly, while DCI’s activity is more tied to glycogen synthesis, and the two accumulate in different ratios in different tissues. That tissue-specific split is the entire reason a “ratio” question exists at all — if the two forms did the same thing everywhere in the body, no one would need to argue about the proportion.

Practically: myo-inositol is the more abundant form and the one most ovulation and insulin trials have used on its own, at 2 to 4 grams a day — that dosing question is covered in full in inositol for PCOS. D-chiro-inositol is the less abundant form, converted from MI by the epimerase enzyme as needed, and it is where this article’s actual subject — the ratio between the two — becomes relevant.

You may also see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), the name a 2026 global consensus of 56 organisations adopted for the same condition. The inositol research below predates and postdates that change equally; only the label moved. See PCOS is now PMOS for the full rename.

Where Does the 40:1 Ratio Actually Come From?

The 40:1 figure is named for the myo-inositol-to-D-chiro-inositol ratio normally found in human blood plasma, and a 2019 trial built its dosing directly around that plasma ratio to test whether reproducing it orally would restore ovulation. It is not an arbitrary marketing number — it is an attempt to match a supplement dose to a naturally occurring physiological proportion, on the theory that recreating the body’s own balance would work better than either isomer given alone or in an invented ratio.

What Is the “D-Chiro-Inositol Paradox” in the Ovary?

A 2011 paper coined this exact term to describe why more DCI is not simply better: the ovary appears to run on a different local ratio than the rest of the body. The epimerase enzyme that converts MI into DCI is insulin-dependent, and researchers have proposed that in the ovaries of women with PCOS, that enzyme runs harder than it should, converting away too much local MI and leaving the ovary short of the myo-inositol it needs — which is linked to poorer oocyte quality. In plain terms: DCI is genuinely useful for insulin signalling in tissues like muscle and liver, but pushing the ovary’s local supply too far toward DCI may work against egg quality specifically, even while helping the metabolic picture elsewhere. That is the paradox — the same molecule, at the same time, being helpful in one tissue and potentially counterproductive in another.

What Actually Changes as the Ratio Shifts Toward More DCI?

Two trials, run twenty years apart in 1999 and 2019, point in overlapping but not identical directions, and both results are real. Systemic insulin signalling — the kind measured in blood glucose, fasting insulin, and triglycerides — responded well to DCI given entirely on its own in the 1999 trial. The ovary, measured through ovulation and hormone normalisation, responded best to a formulation that was 40 parts MI to every 1 part DCI, and got worse as DCI’s share rose.

What Did the Ratio Trial Actually Test?

Fifty-six women with PCOS were split into seven groups of eight and given one of seven myo-inositol-to-D-chiro-inositol combinations — DCI alone, 1:3.5, 2.5:1, 5:1, 20:1, 40:1, or 80:1 — all at a total dose of 2 g of combined inositols twice daily for three months, with ovulation as the primary outcome.

The trial’s own conclusion was specific: DCI is beneficial mainly at this particular ratio with MI, and increasing DCI beyond it caused the benefit to fall away rather than grow — a result the authors noted matched an earlier preclinical study using different MI/DCI ratios in a PCOS mouse model.

Does Deviating From 40:1 Matter in Practice?

The honest answer is: probably somewhat — the 2019 trial tested seven fixed ratios, not a continuous range, so it cannot say exactly how much drift from 40:1 is tolerable. What it showed is that ratios meaningfully far from 40:1 — a DCI-dominant 1:3.5, for example — underperformed it; it did not test whether a product labelled 35:1 or 45:1 behaves any differently from one labelled exactly 40:1. Separately, entirely MI-only products with no DCI at all have shown real ovulation and insulin benefits in their own trials — covered in full in inositol for PCOS, which owns the dosing question — which suggests that hitting an adequate total myo-inositol dose matters at least as much as hitting the ratio exactly. Treat “40:1” as a reasonable target worth checking for on a combination product’s label, not as a number precise enough to reject a product over a few points either way.

To check a label yourself, divide the myo-inositol milligrams by the D-chiro-inositol milligrams. A product listing 2,000 mg myo-inositol and 50 mg D-chiro-inositol per serving works out to 2,000 ÷ 50 = 40, so it is on-ratio. One listing 1,000 mg myo-inositol and 100 mg D-chiro-inositol works out to 10:1 — a DCI-heavier formulation than the trial evidence above supports for ovulation, whatever its metabolic marketing claims.

Is D-Chiro-Inositol Alone Ever the Right Choice?

Yes, for a different goal: the original 1999 trial of DCI alone in 44 obese women with PCOS found 19 of 22 treated participants ovulated within six to eight weeks, alongside real drops in insulin, free testosterone, and triglycerides — DCI by itself clearly has a metabolic and reproductive effect. The 2024 systematic review that fed the 2023 international guideline update noted the same pattern: “potential benefits from DCI for ovulation,” alongside evidence for myo-inositol on some metabolic measures — while also rating the overall inositol evidence base “limited and inconclusive.” DCI alone is a reasonable, trial-backed option on its own terms. The paradox above is specifically about pushing the ovary’s local ratio too far toward DCI long-term inside a combination product, not a claim that DCI itself is harmful.

What neither trial answers is which is better for you specifically: nobody has run DCI alone against a 40:1 combination head-to-head in the same participants over the same period. The 1999 DCI trial ran 6 to 8 weeks in obese women selected for insulin resistance; the 40:1 ratio trial ran 3 months across seven groups of only 8 women each. Both are genuine findings and both are small. Neither result should be read as settling the question against the other.

Who Should Not Assume the Ratio Is the Main Variable?

Two variables matter more than the ratio for many readers: whether the total dose reaches the 2–4 g of combined inositols that showed benefit above, and whether gastrointestinal tolerability is the real complaint. If tolerability is the actual problem, changing the ratio will not fix it — that comes down to total inositol dose, and is covered fully in inositol side effects. And if a product’s real issue is that it delivers a fraction of a gram per serving, no ratio precision compensates for an inadequate total dose; check the milligrams before the ratio. Inositol, in any ratio, is a supplement rather than a licensed medicine — a label claiming “clinically proven 40:1” is not independently verified by a regulator the way a prescription drug’s formulation is, and no ratio or dose has been shown to cure or reverse PCOS.

Phenotype matters here too. If your cycles are irregular mainly because of insulin resistance, both plain myo-inositol and a 40:1 combination have real trial support and the ratio question is worth getting right. If insulin resistance is not part of your picture — a lean, regularly-cycling PCOS pattern, for instance — no ratio of these two molecules has been tested specifically in that group, and the more relevant question is probably whether inositol is the right supplement at all, not which ratio of it to buy.

Your Next Step

Two things are worth checking on the bottle in front of you: whether the label states an actual myo-inositol-to-D-chiro-inositol ratio at all (many list only “inositol” with no breakdown), and whether the total daily dose reaches the 2–4 g of combined inositols the trials above tested. A ranked look at how inositol compares with the rest of the evidence-backed supplement options is in the PCOS supplements guide, and the wider supplements and medications section covers everything else worth ruling in or out.